Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. (1r,2s)-1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(3-fluorophenyl)-1-phenyl-butan-2-ol
2. Aids-222089
3. Aids222088
4. Bedaquiline
5. R207910
6. Tmc207
1. 845533-86-0
2. Bedaquiline (fumarate)
3. Sirturo
4. R403323
5. Bedaquiline Fumarate [usan]
6. P04qx2c1a5
7. Chebi:72295
8. 845533-86-0 (fumarate)
9. R-403323
10. R 403323
11. Unii-p04qx2c1a5
12. (1r,2s)-1-(6-bromo-2-methoxy-3-quinolyl)-4-dimethylamino-2-(1-naphthyl)-1-phenyl-butan-2-ol Fumarate
13. Bedaquilinefumarate
14. Sirturo (tn)
15. Chembl2105700
16. Schembl20496928
17. Bedaquiline Fumarate [mi]
18. Bedaquiline Fumarate; R403323
19. Bedaquiline Fumarate (jan/usan)
20. Bedaquiline Fumarate [jan]
21. Dtxsid401004837
22. Ex-a2647
23. Hy-14881a
24. S4854
25. Bedaquiline Fumarate [who-dd]
26. Ccg-270358
27. Ac-28750
28. As-57710
29. Bedaquiline Fumarate [orange Book]
30. D09873
31. R403323;tmc207 Fumarate;r207910 Fumarate
32. Q27139886
33. (1r,2s)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(1-naphthyl)-1-phenylbutan-2-ol Bis[(2z)-but-2-enedioate]
34. (1r,2s)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1- Phenylbutan-2-ol (2e)-but-2-enedioate Salt (1:1)
35. (1r,2s)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol Fumarate
36. (1r,2s)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol;(e)-but-2-enedioic Acid
37. 3-quinolineethanol, 6-bromo-.alpha.-(2-(dimethylamino)ethyl)-2-methoxy-.alpha.-1-naphthalenyl-.beta.-phenyl-, (.alpha.s,.beta.r)-, (2e)-2-butenedioate (1:1) (salt)
38. 3-quinolineethanol, 6-bromo-alpha-(2-(dimethylamino)ethyl)-2-methoxy-alpha-1-naphthalenyl- -phenyl-, (s,r)-, (2e)-2-butenedioate (1:1) (salt)
39. 6-bromo-3-[(1r,2s)-4-(dimethylammonio)-2-hydroxy-2-(1-naphthyl)-1-phenylbutyl]-2-methoxyquinolinium (2e)-but-2-enedioate
Molecular Weight | 671.6 g/mol |
---|---|
Molecular Formula | C36H35BrN2O6 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 10 |
Exact Mass | 670.16785 g/mol |
Monoisotopic Mass | 670.16785 g/mol |
Topological Polar Surface Area | 120 Ų |
Heavy Atom Count | 45 |
Formal Charge | 0 |
Complexity | 834 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Antitubercular Agents
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. (See all compounds classified as Antitubercular Agents.)
J04AK05
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Sirturo (bedaquiline) is an approved ATP synthase inhibitor. It is given orally for the treatment in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Lead Product(s): Bedaquiline
Therapeutic Area: Infections and Infectious Diseases Brand Name: Sirturo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2024
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
J&J’s Sirturo for Tuberculosis Receives Full US, EU Approvals
Details : Sirturo (bedaquiline) is an approved ATP synthase inhibitor. It is given orally for the treatment in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Brand Name : Sirturo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2024
Details:
OPC-167832 (quabodepistat) is a potent and orally active dprE1 inhibitor, which is being evaluated in combination with delamanid & bedaquiline for the treatment of pulmonary tuberculosis.
Lead Product(s): OPC-167832,Delamanid,Bedaquiline
Therapeutic Area: Infections and Infectious Diseases Brand Name: OPC-167832
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Lead Product(s) : OPC-167832,Delamanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Otsuka Reports Interim Phase 2b/c Data Indicating New Compound May Shorten Tuberculosis
Details : OPC-167832 (quabodepistat) is a potent and orally active dprE1 inhibitor, which is being evaluated in combination with delamanid & bedaquiline for the treatment of pulmonary tuberculosis.
Brand Name : OPC-167832
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2024
Details:
Sirturo (bedaquiline) is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Lead Product(s): Bedaquiline
Therapeutic Area: Infections and Infectious Diseases Brand Name: Sirturo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2023
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sirturo (bedaquiline) is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Brand Name : Sirturo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 07, 2023
Details:
This program is evaluating two novel drug regimens comprising five antibacterial agents—bedaquiline, delamanid, pretomanid, quabodepistat (formerly known as OPC-167832), and sutezolid.
Lead Product(s): Delamanid,Bedaquiline,OPC-167832
Therapeutic Area: Infections and Infectious Diseases Brand Name: Deltyba
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Bill & Melinda Gates Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Lead Product(s) : Delamanid,Bedaquiline,OPC-167832
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bill & Melinda Gates Foundation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This program is evaluating two novel drug regimens comprising five antibacterial agents—bedaquiline, delamanid, pretomanid, quabodepistat (formerly known as OPC-167832), and sutezolid.
Brand Name : Deltyba
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 09, 2023
Details:
The PAN-TB collaboration is a first-of-its-kind effort to accelerate development of a drug regimen capable of treating all forms of TB, and identifying promising regimens for further development including OPC-167832.
Lead Product(s): OPC-167832,Delamanid,Bedaquiline
Therapeutic Area: Infections and Infectious Diseases Brand Name: OPC-167832
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 17, 2022
Lead Product(s) : OPC-167832,Delamanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The PAN-TB collaboration is a first-of-its-kind effort to accelerate development of a drug regimen capable of treating all forms of TB, and identifying promising regimens for further development including OPC-167832.
Brand Name : OPC-167832
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 17, 2022
Details:
Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Lead Product(s): Pretomanid,Bedaquiline,Linezolid
Therapeutic Area: Infections and Infectious Diseases Brand Name: PA-824
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 06, 2021
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Brand Name : PA-824
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 06, 2021
Details:
The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Lead Product(s): OPC-167832,Delamanid,Bedaquiline
Therapeutic Area: Infections and Infectious Diseases Brand Name: OPC-167832
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Bill & Melinda Gates Foundation
Deal Size: $17.8 million Upfront Cash: Undisclosed
Deal Type: Funding August 10, 2021
Lead Product(s) : OPC-167832,Delamanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Bill & Melinda Gates Foundation
Deal Size : $17.8 million
Deal Type : Funding
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-TB Combo
Details : The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Brand Name : OPC-167832
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2021
Details:
The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.
Lead Product(s): Pretomanid,Bedaquiline,Linezolid
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: PA-824
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.
Brand Name : PA-824
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2020
Details:
SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB).
Lead Product(s): Bedaquiline
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Lead Product(s) : Bedaquiline
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline) as Part of Combination Ther...
Details : SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 27, 2020
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Bedaquiline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bedaquiline, including repackagers and relabelers. The FDA regulates Bedaquiline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bedaquiline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bedaquiline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bedaquiline supplier is an individual or a company that provides Bedaquiline active pharmaceutical ingredient (API) or Bedaquiline finished formulations upon request. The Bedaquiline suppliers may include Bedaquiline API manufacturers, exporters, distributors and traders.
click here to find a list of Bedaquiline suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bedaquiline DMF (Drug Master File) is a document detailing the whole manufacturing process of Bedaquiline active pharmaceutical ingredient (API) in detail. Different forms of Bedaquiline DMFs exist exist since differing nations have different regulations, such as Bedaquiline USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bedaquiline DMF submitted to regulatory agencies in the US is known as a USDMF. Bedaquiline USDMF includes data on Bedaquiline's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bedaquiline USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bedaquiline suppliers with USDMF on PharmaCompass.
A Bedaquiline written confirmation (Bedaquiline WC) is an official document issued by a regulatory agency to a Bedaquiline manufacturer, verifying that the manufacturing facility of a Bedaquiline active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bedaquiline APIs or Bedaquiline finished pharmaceutical products to another nation, regulatory agencies frequently require a Bedaquiline WC (written confirmation) as part of the regulatory process.
click here to find a list of Bedaquiline suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bedaquiline as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bedaquiline API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bedaquiline as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bedaquiline and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bedaquiline NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bedaquiline suppliers with NDC on PharmaCompass.
Bedaquiline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bedaquiline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bedaquiline GMP manufacturer or Bedaquiline GMP API supplier for your needs.
A Bedaquiline CoA (Certificate of Analysis) is a formal document that attests to Bedaquiline's compliance with Bedaquiline specifications and serves as a tool for batch-level quality control.
Bedaquiline CoA mostly includes findings from lab analyses of a specific batch. For each Bedaquiline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bedaquiline may be tested according to a variety of international standards, such as European Pharmacopoeia (Bedaquiline EP), Bedaquiline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bedaquiline USP).
LOOKING FOR A SUPPLIER?